Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.
Investor insights
Funding rounds participated in
$200M sweet spot round size
Investor type
Privately Held
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2023
Funding rounds raised
Total raised
$200M
from investors over 1 rounds
S
Spyre Therapeutics raised $200M on December 18, 2024